Philippe Moreau

Centre National de la Recherche Scientifique

Also affiliated with Inserm, Hotel Dieu Hospital, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Nantes Université

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 19 papers. Top paper: “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma”.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

New England Journal of Medicine(2022)10.1056/nejmoa2204925

N/A

6.2DataRank · unranked

474 citations

Susanna Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur Raje +51 more

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30525-8

N/A

5.3DataRank · unranked

407 citations

Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto +15 more

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8

N/A

4.1DataRank · unranked

307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Leukemia(2020)10.1038/s41375-020-0718-z

N/A

2.9DataRank · unranked

98 citations

Ajai Chari, Yaël C. Cohen, Andrew Spencer, Peter M. Voorhees, Jane Estell +16 more

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Journal of Clinical Oncology(2025)10.1200/jco-24-01893

N/A

2.3DataRank · unranked

151 citations

Faith E. Davies, Mehmet Samur, Jill Corre, Mattia D’Agostino, Martin Kaiser +41 more

Dabrafenib plus trametinib in patients with relapsed/refractoryBRAFV600E mutation–positive hairy cell leukemia

Blood(2022)10.1182/blood.2021013658

N/A

1.1DataRank · unranked

42 citations

Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne‐Sophie Michallet +12 more

Polymorphic Sites at the 3’ Untranslated Region of the HLA-G Gene Are Associated with Differential hla-g Soluble Levels in the Brazilian and French Population

PLoS ONE(2013)10.1371/journal.pone.0071742

N/A

0.801DataRank · unranked

207 citations

Joao A. Pancotto, Yara C. Muniz, Celso T. Mendes-Junior, Erick C. Castelli, Juliana D. Massaro +8 more

Timing the initiation of multiple myeloma

Nature Communications(2020)10.1038/s41467-020-15740-9

N/A

0.767DataRank · unranked

165 citations

Venkata D. Yellapantula, Daniel Leongamornlert, Niccolò Bolli, Guy Ledergor, Ferran Nadeu +21 more

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors

Blood Cancer Journal(2022)10.1038/s41408-022-00759-6

N/A

0.690DataRank · unranked

25 citations

Mariateresa Fulciniti, Hervé Avet‐Loiseau, Michael Lopez, Sanika Derebail, Jill Corre +8 more

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Blood(2024)10.1182/blood.2023023597

N/A

0.617DataRank · unranked

60 citations

Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien +11 more

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Blood(2023)10.1182/blood.2022017094

N/A

0.584DataRank · unranked

48 citations

Marco Roncador, Anıl Aktaş Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphaël Szalat +14 more

Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

Leukemia(2021)10.1038/s41375-021-01250-0

N/A

0.561DataRank · unranked

41 citations

Aurore Perrot, Cyrille Hulin, Denis Caillot, Anne‐Marie Stoppa, Thierry Façon +25 more

Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens

Cells(2021)10.3390/cells10020438

N/A

0.396DataRank · unranked

13 citations

Nicolas Mennesson, Cassandra Lepetit, Maeva Fourny, Margaux Louvois, Adrien Bosseboeuf +10 more

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

British Journal of Haematology(2023)10.1111/bjh.18772

N/A

0.312DataRank · unranked

7 citations

Frederique Kuhnowski, Benoit Berge, Murielle Roussel, Laure Devlamynck, Marie Odile Petillon +20 more

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse

British Journal of Haematology(2025)10.1111/bjh.19978

N/A

0.312DataRank · unranked

7 citations

Xavier Leleu, Mourad Tiab, Margaret Macro, Aurore Perrot, Julie Gay +21 more

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

The Lancet Haematology(2025)10.1016/s2352-3026(25)00139-5

N/A

0.241DataRank · unranked

4 citations

Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto +13 more

Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.8016

N/A

0.165DataRank · unranked

2 citations

Hannah Seah, Vaishnavi Reddy Bade, Arthur Krogman, Shree Acharya, Andreea Negroiu +13 more

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma

HemaSphere(2025)10.1002/hem3.70178

N/A

0DataRank · unranked

1 citations

Noa Biran, Elizabeth O’Donnell, Joseph Mıkhael, Katja Weisel, Annemiek Broijl +8 more

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

The Lancet Haematology(2022)10.1016/s2352-3026(22)00045-x

N/A

0DataRank · unranked

24 citations

Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck +35 more